Business
WallStreet Research™ Announces Availability of Corporate Profile Coverage on Nemaura Medical, Inc.
WallStreet Research™ Announces Availability of Corporate Profile Coverage on Nemaura Medical, Inc..
About this update from Nemaura Medical, Inc.
[{"type":"text","content":"\n \n WallStreet Research™ (WSR), a top-ranked independent research firm with \n a history spanning over three decades, today announced that it has \n initiated Corporate Profile coverage on Nemaura Medical, Inc. (OTCQB: \n NMRD) (the “Company”). WallStreet Research™ is ranked Number One on the \n Google, Yahoo, and Bing search engines for both small and micro-cap \n research with a global following. A Corporate Profile Report, together \n with additional information about WallStreet Research™, is available at \n the www.WallStreetResearch.org \n website. The WSR Corporate Profile highlights the Company’s recent \n accomplishments and growth plans for 2017 and beyond.\n \n \n Nemaura Medical Inc. (OTCQB:NMRD) is a medical technology company based \n in Loughborough Science Park in the United Kingdom (incorporated in \n Nevada) developing sugarBEAT® as a patent protected \n non-invasive, affordable and flexible glucose monitoring system. \n European clinical trials for sugarBEAT® are expected to be \n completed by end of November 2017, with product launch anticipated \n shortly afterwards in the United Kingdom.\n \n \n SugarBEAT® consists of a disposable adhesive skin-patch \n connected to a rechargeable transmitter, with an app displaying glucose \n readings, and is expected to empower both type I and type II diabetics \n to better manage glucose levels, thereby helping prevent or delay long \n term medical complications.\n \n \n The Company’s underlying BEAT technology platform has the potential to \n transform health monitoring by providing non-invasive feedback on \n analytes including amino acid, oxygen, lactate and a range of \n prescription medicines.\n \n \n Mr. Alan Stone, Managing Director of WallStreet Research™ commented, \n “The European Diabetes device market consists of approximately 31 \n million people living with diabetes, and this market is expected to grow \n significantly in the coming decade. We believe that Nemaura Medical is \n well positioned to soon penetrate this market with a well designed \n alternative new technology.”\n \n \n On August 9, 2017, the Company reported First Quarter 2017 financial \n results for the period ending June 30. Research and Development expenses \n fell to $149,198 for the quarter ended June 2017, a dec...